Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery

Beck, 2014, Antibody-drug conjugates present and future, MAbs, 6, 15, 10.4161/mabs.27436 Beck, 2017, Strategies and challenges for the next generation of antibody—drug conjugates, Nat Rev Drug Discov, 16, 315, 10.1038/nrd.2016.268 Deonarain, 2018, Small-format drug conjugates: a viable alternative to ADCs for solid tumours?, Antibodies, 7, 16, 10.3390/antib7020016 European Medicines Agency (2012) Adcetris CHMP Assessment Report, EMA/702390/2012. McDonagh, 2008, Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index, Mol Cancer Ther, 7, 2913, 10.1158/1535-7163.MCT-08-0295 Chudasama, 2016, Recent advances in the construction of antibody—drug conjugates, Nat Chem, 8, 114, 10.1038/nchem.2415 Junutula, 2008, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index, Nat Biotechnol, 26, 925, 10.1038/nbt.1480 Pillow, 2014, Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering, J Med Chem, 57, 7890, 10.1021/jm500552c Badescu, 2014, Bridging disulfides for stable and defined antibody drug conjugates, Bioconjug Chem, 25, 1124, 10.1021/bc500148x Schumacher, 2013, Homogeneous antibody fragment conjugation by disulfide bridging introduces ‘spinostics’, Sci Rep, 3, 10.1038/srep01525 Nunes, 2015, Functional native disulfide bridging enables delivery of a potent, stable and targeted antibody–drug conjugate (ADC), Chem Commun, 51, 10624, 10.1039/C5CC03557K Maruani, 2015, A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy, Nat Commun, 6, 10.1038/ncomms7645 Robinson, 2017, Pyridazinediones deliver potent, stable, targeted and efficacious antibody–drug conjugates (ADCs) with a controlled loading of 4 drugs per antibody, RSC Adv, 7, 9073, 10.1039/C7RA00788D Lee, 2017, Enabling the controlled assembly of antibody conjugates with a loading of two modules without antibody engineering, Chem Sci, 8, 2056, 10.1039/C6SC03655D Bahou, 2018, Highly homogeneous antibody modification through optimisation of the synthesis and conjugation of functionalised dibromopyridazinediones, Org Biomol Chem, 16, 1359, 10.1039/C7OB03138F Brinkmann, 2017, The making of bispecific antibodies, MAbs, 9, 182, 10.1080/19420862.2016.1268307 Banta, 2013, Replacing antibodies: engineering new binding proteins, Annu Rev Biomed Eng, 15, 93, 10.1146/annurev-bioeng-071812-152412 Mouratou, 2015, Artificial affinity proteins as ligands of immunoglobulins, Biomolecules, 5, 60, 10.3390/biom5010060 Škrlec, 2015, Non-immunoglobulin scaffolds: a focus on their targets, Trends Biotechnol, 33, 408, 10.1016/j.tibtech.2015.03.012 Sha, 2017, Monobodies and other synthetic binding proteins for expanding protein science, Protein Sci, 26, 910, 10.1002/pro.3148 Gebauer, 2009, Engineered protein scaffolds as next-generation antibody therapeutics, Curr Opin Chem Biol, 13, 245, 10.1016/j.cbpa.2009.04.627 Greene, 2018, Generating next-generation antibody-nanoparticle conjugates through the oriented installation of non-engineered antibody fragments, Chem Sci, 9, 79, 10.1039/C7SC02747H Richards, 2016, Photochemically re-bridging disulfide bonds and the discovery of a thiomaleimide mediated photodecarboxylation of C-terminal cysteines, Org Biomol Chem, 14, 455, 10.1039/C5OB02120K Zhao, 2009, Two routes for production and purification of Fab fragments in biopharmaceutical discovery research: papain digestion of mAb and transient expression in mammalian cells, Protein Expr Purif, 67, 182, 10.1016/j.pep.2009.04.012 Wang, 2007, In vitro efficacy of immuno-chemotherapy with anti-EGFR human Fab-taxol conjugate on A431 epidermoid carcinoma cells, Cancer Biol Ther, 6, 980, 10.4161/cbt.6.6.4197 Chen, 2013, A human anti-c-met fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma, PLoS One, 8 https://www.abzena.com. [Accessed 03 September 2018]. Crivianu-Gaita, 2016, Aptamers, antibody scFv, and antibody Fab′ fragments: an overview and comparison of three of the most versatile biosensor biorecognition elements, Biosens Bioelectron, 85, 32, 10.1016/j.bios.2016.04.091 Ahmad, 2012, ScFv antibody: principles and clinical application, Clin Dev Immunol, 2012, 10.1155/2012/980250 Lipovšek, 2018, Adnectin – drug conjugates for Glypican-3-specific delivery of a cytotoxic payload to tumors, Protein Eng Des Sel, 1 Hull, 2014, Homogeneous bispecifics by disulfide bridging, Bioconjug Chem, 25, 1395, 10.1021/bc5002467 Bhatti, 2008, Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments, Int J Cancer, 122, 1155, 10.1002/ijc.23206 Deonarain PD, Yahiogl MP, Stamati G, Saouros I, Kapadnis S, Deonarain MP, et al. Biological materials and uses thereof, WO/2016/046574, 31 March 2016. Deonarain, 2017, Fragment antibody fragment drug conjugates (FDCs): a unique drug class or just smaller ADCs? Safdari, 2016, Use of single-chain antibody derivatives for targeted drug delivery, Mol Med, 22, 258, 10.2119/molmed.2016.00043 Chen, 2014, Anti-hepatoma human single-chain Fv antibody and adriamycin conjugates with potent antitumor activity, Int Immunopharmacol, 18, 20, 10.1016/j.intimp.2013.11.002 Zhao, 2012, A conjugate of an anti-midkine single-chain variable fragment to doxorubicin inhibits tumor growth, Braz J Med Biol Res, 45, 230, 10.1590/S0100-879X2012007500009 Kuimova, 2007, Fluorescence characterisation of multiply-loaded anti-HER2 single chain Fv-photosesitizer conjugates suitable for photodynamic therapy, Photochem Photobiol Sci, 6, 933, 10.1039/b708320c Bauerschlag, 2017, Detection and specific elimination of EGFR+ ovarian cancer cells using a near infrared photoimmunotheranostic approach, Pharm Res, 34, 696, 10.1007/s11095-017-2096-4 http://www.antikor.co.uk/. [Accessed 03 September 2018]. Todorovska, 2001, Design and application of diabodies, triabodies and tetrabodies for cancer targeting, J Immunol Methods, 248, 47, 10.1016/S0022-1759(00)00342-2 Johnson, 2010, Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion, J Mol Biol, 399, 436, 10.1016/j.jmb.2010.04.001 Zhu, 1996, High level secretion of a humanized bispecific diabody from Escherichia coli, Biotechnology, 14, 192 Kim, 2008, Anti-CD30 diabody-drug conjugates with potent antitumor activity, Mol Cancer Ther, 7, 2486, 10.1158/1535-7163.MCT-08-0388 Hudson PJ, Tamvakis D, Wheatcroft MP, Turatti F, Immuno-conjugates and methods for producing them, patent number 9290577, March 22nd 2016. Olafsen, 2004, Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications, Protein Eng Des Sel, 17, 21, 10.1093/protein/gzh009 Sirk, 2008, Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2, Bioconjug Chem, 19, 2527, 10.1021/bc800113v Walseng, 2016, Chemically programmed bispecific antibodies in diabody format, J Biol Chem, 291, 19661, 10.1074/jbc.M116.745588 Klöhn, 2013, IBC’s 23rd annual antibody engineering, 10th annual antibody therapeutics international conferences and the 2012 annual meeting of the antibody society: december 3–6, 2012, San Diego, CA, MAbs, 5, 178, 10.4161/mabs.23655 http://www.avipep.com.au/technology/background-on-avibodies/. Li, 1997, Mammalian cell expression of dimeric small immune proteins (SIP), Protein Eng, 10, 731, 10.1093/protein/10.6.731 Borsi, 2002, Selective targeting of tumoral vasculature: comparison of different formats of an antibody (l19) to the ED-B domain of fibronectin, Int J Cancer, 102, 75, 10.1002/ijc.10662 Silacci, 2006, Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo, Protein Eng Des Sel, 19, 471, 10.1093/protein/gzl033 Bernardes, 2012, A traceless vascular-targeting antibody-drug conjugate for cancer therapy, Angew Chem Int Ed, 51, 941, 10.1002/anie.201106527 Steiner, 2013, Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature, Chem Sci, 4, 297, 10.1039/C2SC21107F Perrino, 2014, Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids, Cancer Res, 74, 2569, 10.1158/0008-5472.CAN-13-2990 Gebleux, 2015, Antibody format and drug release rate determine the therapeutic activity of noninternalizing antibody-drug conjugates, Mol Cancer Ther, 14, 2606, 10.1158/1535-7163.MCT-15-0480 Gébleux, 2017, Non-internalizing antibody–drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix, Int J Cancer, 140, 1670, 10.1002/ijc.30569 Poli, 2013, Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study, Cancer Immunol Res, 1, 10.1158/2326-6066.CIR-13-0007 http://www.philogen.com/en/. [Accessed 03 September 2018]. Nilvebrant, 2013, The albumin-binding domain as a scaffold for protein engineering, Comput Struct Biotechnol J, 6, 10.5936/csbj.201303009 Löfblom, 2010, Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications, FEBS Lett, 584, 2670, 10.1016/j.febslet.2010.04.014 Ståhl, 2017, Affibody molecules in biotechnological and medical applications, Trends Biotechnol, 35, 691, 10.1016/j.tibtech.2017.04.007 Frejd, 2017, Affibody molecules as engineered protein drugs, Exp Mol Med, 49, 10.1038/emm.2017.35 Ekblad, 2009, Synthesis and chemoselective intramolecular crosslinking of a HER2-binding affibody, Biopolymers, 92, 116, 10.1002/bip.21142 Lindgren, 2010, N-terminal engineering of amyloid-β-binding Affibody molecules yields improved chemical synthesis and higher binding affinity, Protein Sci, 19, 2319, 10.1002/pro.511 Engfeldt, 2005, Chemical synthesis of triple-labelled three-helix bundle binding proteins for specific fluorescent detection of unlabelled protein, ChemBioChem, 6, 1043, 10.1002/cbic.200400388 Malm, 2013, Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification, PLoS One, 8, 10.1371/annotation/0d29f87c-8dfb-4694-abc7-7284a970910d Feldwisch, 2010, Design of an optimized scaffold for affibody molecules, J Mol Biol, 398, 232, 10.1016/j.jmb.2010.03.002 Kramer-Marek, 2008, [18F]FBEM-ZHER2:342-Affibody molecule — a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography, Eur J Nucl Med Mol Imaging, 35, 1008, 10.1007/s00259-007-0658-0 Kiesewetter, 2008, Radiolabeling of HER2-specific Affibody® molecule with F-18, J Fluor Chem, 129, 799, 10.1016/j.jfluchem.2008.06.021 Sochaj-Gregorczyk, 2016, A novel affibody-auristatin E conjugate with a potent and selective activity against HER2 + cell lines, J Immunother, 39, 223, 10.1097/CJI.0000000000000125 Sochaj-Gregorczyk, 2017, Design and in vitro evaluation of a cytotoxic conjugate based on the anti-HER2 affibody fused to the Fc fragment of IgG1, Int J Mol Sci, 18, 10.3390/ijms18081688 http://www.affibody.se. [Accessed 03 September 2018]. Koide, 2012, Target-binding proteins based on the 10th human fibronectin type III domain (10Fn3), Methods Enzymol, 503, 135, 10.1016/B978-0-12-396962-0.00006-9 Diem, 2014, Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions, Protein Eng Des Sel, 27, 419, 10.1093/protein/gzu016 Koide, 2002, Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor, Proc Natl Acad Sci U S A, 99, 1253, 10.1073/pnas.032665299 Wojcik, 2010, A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain, Nat Struct Mol Biol, 17, 519, 10.1038/nsmb.1793 Goldberg, 2016, Engineering a targeted delivery platform using Centyrins, Protein Eng Des Sel, 29, 563 https://www.janssen.com/biotherapeutics/antibodies/. [Accessed 03 September 2018]. Plückthun, 2015, Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy, Annu Rev Pharmacol Toxicol, 55, 489, 10.1146/annurev-pharmtox-010611-134654 Zahnd, 2007, A designed ankyrin repeat protein evolved to picomolar affinity to Her2, J Mol Biol, 369, 1015, 10.1016/j.jmb.2007.03.028 Schilling, 2014, From DARPins to LoopDARPins: novel LoopDARPin design allows the selection of low picomolar binders in a single round of ribosome display, J Mol Biol, 426, 691, 10.1016/j.jmb.2013.10.026 Boersma, 2011, Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling, J Biol Chem, 286, 41273, 10.1074/jbc.M111.293266 Simon, 2013, Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension, Bioconjug Chem, 24, 1955, 10.1021/bc4004102 Simon, 2014, Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation, Mol Cancer Ther, 13, 375, 10.1158/1535-7163.MCT-13-0523 Sokolova, 2016, Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo, J Control Release, 233, 48, 10.1016/j.jconrel.2016.05.020 Mao, 2016, The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer, Oncotarget, 7, 24810, 10.18632/oncotarget.8529 https://www.molecularpartners.com/. [Accessed 03 September 2018]. Cox, 2016, Integrin-targeting knottin peptide–drug conjugates are potent inhibitors of tumor cell proliferation, Angew Chem Int Ed, 55, 9894, 10.1002/anie.201603488 Currier, 2016, TArgeted drug delivery with an integrin-binding Knottin–Fc–MMAF conjugate produced by cell-free protein synthesis, Mol Cancer Ther, 15, 1291, 10.1158/1535-7163.MCT-15-0881 http://www.cyclogenix.com. [Accessed 03 September 2018]. Kolmar, 2008, Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins, FEBS J, 275, 2684, 10.1111/j.1742-4658.2008.06440.x Kintzing, 2016, Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles, Curr Opin Chem Biol, 34, 143, 10.1016/j.cbpa.2016.08.022 Iyer, 2011, Tying the knot: the cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines, FEBS J, 278, 4304, 10.1111/j.1742-4658.2011.08350.x Glotzbach, 2013, Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1, PLoS One, 8, 10.1371/journal.pone.0076956 Avrutina, 2004, Fmoc-assisted synthesis of a 29-residue cystine-knot trypsin inhibitor containing a guaninyl amino acid at the P1-position, Eur J Org Chem, 4931, 10.1002/ejoc.200400440 Eyraud, 2013, Expression and biological activity of the cystine knot bioinsecticide PA1b (Pea Albumin 1 subunit b), PLoS One, 8, 10.1371/journal.pone.0081619 Kim, 2015, A chemically cross-linked knottin dimer binds integrins with picomolar affinity and inhibits tumor cell migration and proliferation, J Am Chem Soc, 137, 6, 10.1021/ja508416e Kimura, 2009, Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low-nanomolar affinity, Proteins Struct Funct Bioinform, 77, 359, 10.1002/prot.22441 Muchekehu, 2013, THe effect of molecular weight, PK, and valency on tumor biodistribution and efficacy of antibody-based drugs, Transl Oncol, 6, 562, 10.1593/tlo.13409 Fujimori, 1989, Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2, and Fab in tumors, Cancer Res, 49, 5656 Schneider, 2009, In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1 engineered antibody fragments in LNCaP tumor-bearing nude mice, J Nucl Med, 50, 435, 10.2967/jnumed.108.055608 Garousi, 2016, PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR 2377 affibody molecules, Int J Oncol, 48, 1325, 10.3892/ijo.2016.3369 Orlova, 2006, Tumor imaging using a picomolar affinity HER2 binding Affibody molecule, Cancer Res, 66, 4339, 10.1158/0008-5472.CAN-05-3521 Vorobyeva, 2018, Comparative evaluation of radioiodine and technetium-labeled DARPin 9_29 for radionuclide molecular imaging of HER2 expression in malignant tumors, Contrast Media Mol Imaging, 2018, 10.1155/2018/6930425 Mahalingam, 2017, Evaluation of a centyrin-based near-infrared probe for fluorescence-guided surgery of epidermal growth factor receptor positive tumors, Bioconjug Chem, 28, 2865, 10.1021/acs.bioconjchem.7b00566 Kimura, 2009, Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects, Cancer Res, 69, 2435, 10.1158/0008-5472.CAN-08-2495 Liu, 2011, PET imaging of integrin positive tumors using f labeled knottin peptides, Theranostics, 1, 403, 10.7150/thno/v01p0403 Chevalier, 2017, Massively parallel de novo protein design for targeted therapeutics, Nature, 550, 74, 10.1038/nature23912 Högbom, 2003, Structural basis for recognition by an in vitro evolved affibody, Proc Natl Acad Sci U S A, 100, 3191, 10.1073/pnas.0436100100 Ramamurthy, 2012, Structures of adnectin/protein complexes reveal an expanded binding footprint, Structure, 20, 259, 10.1016/j.str.2011.11.016 Seeger, 2013, Design, construction, and characterization of a second-generation DARPin library with reduced hydrophobicity, Protein Sci, 22, 1239, 10.1002/pro.2312 Root, 2016, Development of PF-06671008, a highly potent anti-P-cadherin/Anti-CD3 bispecific DART molecule with extended half-life for the treatment of cancer, Antibodies, 5, 10.3390/antib5010006 Bloch, 2017, Structural activation of pro-inflammatory human cytokine IL-23 by cognate IL-23 receptor Enables recruitment of the shared receptor IL-12Rβ1, Immunity, 48, 45, 10.1016/j.immuni.2017.12.008 Krätzner, 2005, Structure of Ecballium elaterium trypsin inhibitor II (EETI-II): a rigid molecular scaffold, Acta Cryst, D61, 1255 Tu, 2016, A combination of structural and empirical analyses delineates the key contacts mediating stability and affinity increases in an optimized biotherapeutmrtic single-chain Fv (scFv), J Biol Chem, 291, 1267, 10.1074/jbc.M115.688010